According to filings with the U.S. Securities and Exchange Commission, Blue Arbor Technologies is raising up to $10,174,987.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Blue Arbor Technologies
Blue Arbor Technologies is a medical device company focused on developing advanced neuroprosthetic interfaces that enable intuitive, precise control of prosthetic limbs for people with limb loss. Its core technology is a revolutionary implantable neuromuscular interface that detects voluntary nerve and muscle control signals and translates them into naturalistic, multidegree-of-freedom movements of prosthetic hands and arms. The companys first product, the RESTORE External Sensing Unit (ESU), is a small wearable device connected to fine percutaneous wires that accurately collects biological motor commands and sends them to a receiver within the prosthetic hand, allowing simultaneous individual finger and wrist movements that are not possible with conventional control systems. Blue Arbors products are built on more than 20 years of basic science and clinical research in nerve regeneration, prosthetic interfaces, and rehabilitation after limb loss, supported by over $55 million in research funding, underscoring its strong scientific foundation and leadership position in next-generation prosthetic control. Through this combination of cutting-edge engineering, long-term clinical research, and substantial investment, Blue Arbor Technologies aims to transform prosthetic rehabilitation by giving users more natural, accurate, and reliable control of their artificial limbs.

To learn more, visit https://www.bluearbortech.com/
LinkedIn: https://www.linkedin.com/company/blue-arbor-technologies-inc

Contact:
Noel Borton, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.